Pharmaceutical Advisory Boards

$3,495.00

Use this study to perfect the management of your pharmaceutical advisory boards. Benchmarking data focus on clinical, marketing and payer ad boards across company sizes, markets, and meeting levels. See preferred education/backgrounds for ad board participants, and get practical advice from industry leaders. In-depth benchmarks focus on logistics such as hours needed for ad board preparation, number of participants, ideal length of individual meetings and of member contracts. Compare ad board cost drivers and examine outsourcing patterns. Metrics include total costs, costs per advisory board type and year-over-year spending — data that impact meeting logistics and shape strategy setting. Finally, 14 case studies enable at-a-glance comparisons against your ad boards.

Download a benchmarking report summarySpeak to a pharmaceutical benchmarking expert

Report Details

Publication Date: September 2013
Pages: 188
Chapters: 4
Metrics: 500+
Charts/Graphics: 134

Top Reasons to Buy This Pharmaceutical Advisory Boards Report

Understand Pharmaceutical Advisory Board Spending Levels and Cost Drivers:  Tighter budgets and regulatory restrictions increasingly influence advisory board organizers to do more for less. Reducing costs without compromising meeting quality is essential, as poorly planned advisory boards may fail to provide firms with fully developed opinions and pertinent recommendations.  Aimed at either clinical, marketing or payer initiatives, various types of advisory boards elicit different costs.  Learn what should and shouldn’t be involved in the costs for your next advisory board and how to contain those costs.

Compliance and Regulatory Issues are Impacting How Companies Run Pharmaceutical Advisory Boards:  Compliance concerns surrounding pharmaceutical advisory boards have not been as overwhelming as those for promotional speaker programs or educational “lunch and learn” events. However, ensuring that meetings remain within government guidelines, while keeping them as effective as possible for all involved, is still a challenge for most groups. By implementing the best practices outlined in this report, you can learn how to run regulatory reviews of ad board concepts and avoid holding non-compliant meetings.

Establish Clear Objectives for Your Pharmaceutical Advisory Boards: One of the common challenges leading to an unsuccessful advisory board is that companies fail to set clear objectives for the participants to meet.  Clarifying this objective early in the process will ensure that everyone involved understands the advisory board’s goals and the targeted actionable results.  Follow the step-by-step processes in this report to ensure that you are properly prepared for your next advisory board.

You may also be interested in our medical affairs library as well as individual medical affairs research reports.

Excerpt from Pharmaceutical Advisory Boards

The pharmaceutical industry has always turned to experts and key opinion leaders (KOLs) to shape and inform company policy. Despite increasing rules on how companies are allowed to interact with physicians, this role will continue to be important in furthering the effective development of medicines and ensuring that the benefits of therapies are being communicated to physicians in a useful format. Advisory boards that bring together the right group of experts with a targeted purpose and driven moderator present a huge asset to the industry as a whole.

The proper execution of these three variables — participants, objective and
chairperson — works to ensure advisory boards’ success. First, companies must gather the best potential group of participants to provide cogent answers to their questions. However, even the best advisory boards will be less successful if companies do not establish specific objectives on clinical trial design or marketing initiatives, depending the focus of the meeting. A clear purpose for the meeting with stated goals — both within the meeting and for the company to then act upon the results — is integral to maximizing participants’ time and expertise and meeting company needs. Finally, the importance of an effective and experienced moderator cannot be overstated. This moderator will keep the group on task and move discussion forward. Having a respected and steady chairperson in the room alters the discussions’ dynamics.

Table of Contents

9              Executive Summary

12           Study Methodology

13           Study Definitions

14           Pharmaceutical Advisory Boards: Five Recommendations for Success

22           Conducting Effective and Valuable Advisory Boards

23           Establishing Clear Objectives for Advisory Boards

28           Identifying Constructive Contributors and Moderators

49           Demonstrating Value Through Deliverables and Participant Feedback

51           Advisory Board Challenges and Trends

57           Metrics for Successful Advisory Boards

58           Hours of Preparation for Advisory Board

74           Duration of Advisory Board Meetings

89           Length of Advisory Board Contracts

103         Number of Advisory Board Participants

118         Advisory Board Operations and Costs

119         Advisory Board Management

138         Identifying Advisory Board Cost-Drivers

154         Outsourcing Advisory Board Activities

159         Setting Advisory Board Strategy

160         Advisory Board Case Studies

Charts and Graphics

9              Executive Summary

14           Pharmaceutical Advisory Boards: Five Recommendations for Success

15           Figure E.1: Percentage of Companies Outsourcing Advisory Board Management and Recruitment, by Company Type: North America

16           Figure E.2: Percentage of Companies Outsourcing Specific Advisory Board Functions, by Activity: Europe

22           Conducting Effective and Valuable Advisory Boards

23           Establishing Clear Objectives for Advisory Boards

24           Figure 1.1 Top Reasons for Clinical Advisory Boards: North America

25           Figure 1.2: Top Reasons for Clinical Advisory Boards: Europe

26           Figure 1.3: Top Reasons for Marketing Advisory Boards: North America

27           Figure 1.4: Top Reasons for Marketing Advisory Boards: Europe

28           Figure 1.5: Preferred Years of Clinical Experience for Clinical Advisory Board Members

28           Identifying Constructive Contributors and Moderators

29           Figure 1.6: Preferred Years of Clinical Experience for Marketing Advisory Board Members

30           Figure 1.7: Preferred Years of Advisory Board Experience for Clinical Advisory Board Members

31           Figure 1.8: Preferred Years of Advisory Board Experience for Marketing Advisory Board Members

32           Figure 1.9: Preferred Number of Publications for Clinical Advisory Board Members

33           Figure 1.10: Preferred Number of Publications for Marketing Advisory Board Members

34           Figure 1.11: Preferred Characteristics for Payer Advisory Board Members

36           Figure 1.12: Preferred Education/ Background for National Clinical Advisory Board Members: North America

37           Figure 1.13: Preferred Education/Background for Regional/Local Clinical Advisory Board Members: North America

37           Figure 1.14: Preferred Education/Background for Multinational Clinical Advisory Board Members: North America

38           Figure 1.15: Preferred Education/Background for National Marketing Advisory Board Members: North America

39           Figure 1.16: Preferred Education/Background for Regional/Local Marketing Advisory Board Members: North America

39           Figure 1.17: Preferred Education/Background for Multinational Marketing Advisory Board Members: North America

40           Figure 1.18: Preferred Education/Background for National Clinical Advisory Board Members: Europe

41           Figure 1.19: Preferred Education/Background for Regional/Local Clinical Advisory Board Members: Europe

41           Figure 1.20: Preferred Education/Background for Multinational Clinical Advisory Board Members: Europe

42           Figure 1.21: Preferred Education/Background for National Marketing Advisory Board Members:  Europe

43           Figure 1.22: Preferred Education/Background for Regional/Local Marketing Advisory Board Members: Europe

43           Figure 1.23: Preferred Education/Background for Multinational Marketing Advisory Board Members: Europe

44           Figure 1.24: Preferred Occupation for National Clinical Advisory Board Members

45           Figure 1.25: Preferred Occupation for Regional/Local Clinical Advisory Board Members

45           Figure 1.26: Preferred Occupation for Multinational Clinical Advisory Board Members

46           Figure 1.27: Preferred Occupation for National Marketing Advisory Board Members

47           Figure 1.28: Preferred Occupation for Regional/Local Marketing Advisory Board Members

47           Figure 1.29: Preferred Occupation for Multinational Marketing Advisory Board Members

49           Demonstrating Value Through Deliverables and Participant Feedback

51           Advisory Board Challenges and Trends

51           Figure 1.30: Companies’ Perception of Advisory Board Challenges: Receiving Sufficient Support and Resources

52           Figure 1.31: Companies’ Perception of Advisory Board Challenges: Developing a Strategy

53           Figure 1.32: Companies’ Perception of Advisory Board Challenges: Identifying and Recruiting Members

54           Figure 1.33: Companies’ Perception of Advisory Board Challenges: Ensuring Regulatory Compliance

55           Figure 1.34: Companies’ Perception of Advisory Board Challenges: Coordinating Logistics

56           Figure 1.35: Companies’ Perception of Advisory Board Challenges: Working with Third-Party Vendors

56           Figure 1.36: Companies’ Perception of Advisory Board Challenges: Reporting

57           Metrics for Successful Advisory Boards

58           Hours of Preparation for advisory boards

60           Figure 2.1: Hours of Preparation for Clinical Advisory Boards, by Meeting Type: North America

60           Figure 2.2: Hours of Preparation for Clinical Advisory Boards, by Company: North America

61           Figure 2.3: Hours of Preparation for Clinical Advisory Boards, by Meeting Type: Europe

62           Figure 2.4: Hours of Preparation for Clinical Advisory Boards, by Company: Europe

63           Figure 2.5: Hours of Preparation for Clinical Advisory Boards, by Meeting Type: Developing Markets

64           Figure 2.6: Hours of Preparation for Clinical Advisory Boards, by Company: Developing Markets

66           Figure 2.7: Hours of Preparation for Marketing Advisory Boards, by Meeting Type: North America

66           Figure 2.8: Hours of Preparation for Marketing Advisory Boards, by Company: North America

67           Figure 2.9: Hours of Preparation for Marketing Advisory Boards, by Meeting Type: Europe

68           Figure 2.10: Hours of Preparation for Marketing Advisory Boards, by Company: Europe

70           Figure 2.11: Hours of Preparation for Marketing Advisory Boards, by Meeting Type: Developing Markets

70           Figure 2.12: Hours of Preparation for Marketing Advisory Boards, by Company: Developing Markets

71           Figure 2.13: Hours of Preparation for Payer Advisory Boards, by Region

72           Figure 2.14: Hours of Preparation for Payer Advisory Boards, by Company: North America

73           Figure 2.15: Hours of Preparation for Payer Advisory Boards, by Company: Europe

74           Duration of Advisory Board Meetings

75           Figure 2.16: Duration of Clinical Advisory Board Meetings (in Days), by Meeting Type: North America

76           Figure 2.17: Duration of Clinical Advisory Meetings (in Days), by Company: North America

77           Figure 2.18: Duration of Clinical Advisory Board Meetings (in Days), by Meeting Type: Europe

78           Figure 2.19: Duration of Clinical Advisory Board Meetings (in Days), by Company: Europe

79           Figure 2.20: Duration of Clinical Advisory Board Meetings (in Days), by Meeting Type: Developing Markets

80           Figure 2.21: Duration of Clinical Advisory Board Meetings (in Days), by Company: Developing Markets

81           Figure 2.22: Duration of Marketing Advisory Board Meetings (in Days), by Meeting Type: North America

82           Figure 2.23: Duration of Marketing Advisory Board Meetings (in Days), by Company: North America

83           Figure 2.24: Duration of Marketing Advisory Board Meetings (in Days), by Meeting Type: Europe

84           Figure 2.25: Duration of Marketing Advisory Board Meetings (in Days), by Company: Europe

85           Figure 2.26: Duration of Marketing Advisory Board Meetings (in Days), by Meeting Type: Developing Markets

86           Figure 2.27: Duration of Marketing Advisory Board Meetings (in Days), by Company Type: Developing Markets

87           Figure 2.28: Duration of Payer Advisory Board Meetings (in Days), by Region

88           Figure 2.29: Duration of Payer Advisory Meetings (in Days), by Company: for North America

88           Figure 2.30: Duration of Payer Advisory Board Meetings (in Days), by Company: Europe

89           Length of Advisory Board Contracts

90           Figure 2.31: Length of Contract (in Months) for Clinical Advisory Boards, by Meeting Type: North America

90           Figure 2.32: Length of Contract (in Months) for Clinical Advisory Boards, by Company: North America

91           Figure 2.33: Length of Contract (in Months) for Clinical Advisory Boards, by Meeting Type: Europe

92           Figure 2.34: Length of Contract (in Months) for Clinical Advisory Boards, by Company: Europe

93           Figure 2.35: Length of Contract (in Months) for Clinical Advisory Boards, by Meeting Type: Developing Markets

94           Figure 2.36: Length of Contract (in Months) for Clinical Advisory Boards, by Company: Developing Markets

95           Figure 2.37: Length of Contract (in Months) for Marketing Advisory Boards, by Meeting Type: North America

96           Figure 2.38: Length of Contract (in Months) for Marketing Advisory Boards, by Company: North America

98           Figure 2.39: Length of Contract (in Months) for Marketing Advisory Boards, by Meeting Type: Europe

98           Figure 2.40: Length of Contract (in Months) for Marketing Advisory Boards, by Company: Europe

99           Figure 2.41: Length of Contract (in Months) for Marketing Advisory Boards, by Meeting Type: Developing Markets

100         Figure 2.42: Length of Contract (in Months) for Marketing Advisory Boards, by Company: Developing Markets

101         Figure 2.43: Length of Contract (in Months) for Payer Advisory Boards, by Region

102         Figure 2.44: Length of Contract (in Months) for Payer Advisory Boards, by Company: North America

103         Number of Advisory Board Participants

104         Figure 2.45: Number of Clinical Advisory Board Participants, by Meeting Type: North America

105         Figure 2.46: Number of Clinical Advisory Board Participants, by Company: North America

106         Figure 2.47: Number of Clinical Advisory Board Participants, by Meeting Type: Europe

107         Figure 2.48: Number of Clinical Advisory Board Participants, by Company: Europe

108         Figure 2.49: Number of Clinical Advisory Board Participants, by Meeting Type: Developing Markets

109         Figure 2.50: Number of Clinical Advisory Board Participants, by Company: Developing Markets

110         Figure 2.51: Number of Marketing Advisory Board Participants, by Meeting Type: North America

111         Figure 2.52: Number of Marketing Advisory Board Participants, by Company: North America

112         Figure 2.53: Number of Marketing Advisory Board Participants, by Meeting Type: Europe

113         Figure 2.54: Number of Marketing Advisory Board Participants, by Company: Europe

114         Figure 2.55: Number of Marketing Advisory Board Participants, by Meeting Type: Developing Markets

115         Figure 2.56: Number of Marketing Advisory Board Participants, by Company: Developing Markets

116         Figure 2.57: Number of Payer Advisory Board Participants, by Region

117         Figure 2.58: Number of Payer Advisory Board Participants, by Company: North America

118         Advisory Board Operations and Costs

119         Advisory Board Management

119         Figure 3.1: Departments Responsible for Conducting Advisory Boards: North America

120         Figure 3.2: Departments Responsible for Conducting Advisory Boards: Europe

120         Figure 3.3: Departments Responsible for Conducting Advisory Boards: Developing Markets

124         Figure 3.4: Departments Responsible for Conducting Advisory Boards in North America: Top 10 Companies

125         Figure 3.5: Departments Responsible for Conducting Advisory Boards in North America: Top 50 Companies

125         Figure 3.6: Departments Responsible for Conducting Advisory Boards in Europe: Top 10 and Top 50 Companies

126         Figure 3.7: Departments Responsible for Conducting Advisory Boards in Developing Markets: Top 10 and Top 50 Companies

127         Figure 3.8: Departments Responsible for Conducting Advisory Boards in North America: Small Pharma Companies

127         Figure 3.9: Departments Responsible for Conducting Advisory Boards in North America: Device Companies

128         Figure 3.10: Departments Responsible for Conducting Advisory Boards in Europe: Small and Device Companies

128         Figure 3.11: Departments Responsible for Conducting Advisory Boards in Developing Markets: Small and Device Companies

129         Figure 3.12: Groups Involved in Specific Advisory Board Activities: All North American Companies

130         Figure 3.13: Groups Involved in Specific Advisory Board Activities: European

130         Figure 3.14: Groups Involved in Specific Advisory Board Activities: Developing Markets

131         Figure 3.15: Groups Involved in Specific Advisory Board Activities in North America: Top 10 Companies

131         Figure 3.16: Groups Involved in Specific Advisory Board Activities in North America: Top 50 Companies

132         Figure 3.17: Groups Involved in Specific Advisory Board Activities in North America: Small Pharma Companies

132         Figure 3.18: Groups Involved in Specific Advisory Board Activities in North America: Device Companies

135         Figure 3.19: Average Number of Advisory Boards Conducted per Year, by Meeting Type: North America

136         Figure 3.20: Average Number of Advisory Boards Conducted per Year, by Meeting Type: Europe

137         Figure 3.21: Average Number of Advisory Boards Conducted per Year, by Meeting: Developing Markets

138         Identifying Advisory Board Cost-Drivers

140         Figure 3.22: Cost for Clinical Advisory Boards, by Meeting Type: North America

141         Figure 3.23: Cost for Clinical Advisory Boards, by Company: North America

143         Figure 3.24: Cost for Clinical Advisory Boards, by Meeting Type: Europe

143         Figure 3.25: Cost for Clinical Advisory Boards, by Company: Europe

144         Figure 3.26: Cost for Clinical Advisory Boards, by Meeting Type: Developing Markets

145         Figure 3.27: Cost for Clinical Advisory Boards, by Company: Developing Markets

146         Figure 3.28: Cost for Marketing Advisory Boards, by Meeting Type: North America

147         Figure 3.29: Cost for Marketing Advisory Boards, by Company: North America

148         Figure 3.30: Cost for Marketing Advisory Boards, by Meeting Type: Europe

149         Figure 3.31: Cost for Marketing Advisory Boards, by Company: Europe

150         Figure 3.32: Cost for Marketing Advisory Boards, by Meeting Type: Developing Markets

151         Figure 3.33: Cost for Marketing Advisory Boards, by Company: Developing Markets

152         Figure 3.34: Cost for Payer Advisory Boards, by Region

153         Figure 3.35: Cost for Payer Advisory Boards, by Company: North America

154         Figure 3.36: Percentage of Companies Outsourcing Advisory Board Functions: North America

154         Outsourcing Advisory Board Activities

155         Figure 3.37: Percentage of Companies Outsourcing Advisory Board Functions: Europe

155         Figure 3.38: Percentage of Companies Outsourcing Advisory Board Functions: Developing Markets

156         Figure 3.39: Percentage of Companies Outsourcing Board Management and Recruitment, by Company Type: North America

157         Figure 3.40: Percentage of Companies Outsourcing Advisory Board Functions, by Activity: Europe

159         Setting Advisory Board Strategy

160         Advisory Board Case Studies

162         Figure 4.1: Company 48 Advisory Board Case Study

164         Figure 4.2: Company 42 Advisory Board Case Study

166         Figure 4.3: Company 41 Advisory Board Case Study

168         Figure 4.4: Company 15 Advisory Board Case Study

170         Figure 4.5: Company 25 Advisory Board Case Study

172         Figure 4.6: Company 31 Advisory Board Case Study

174         Figure 4.7: Company 9 Advisory Board Case Study

176         Figure 4.8: Company 9 Advisory Board Case Study

178         Figure 4.9: Company 43 Advisory Board Case Study

180         Figure 4.10: Company 52 Advisory Board Case Study

182         Figure 4.11: Company 13 Advisory Board Case Study

184         Figure 4.12: Company 21 Advisory Board Case Study

186         Figure 4.13: Company 7 Advisory Board Case Study

188         Figure 4.14: Company 16 Advisory Board Case Study